Payment overview · 2025
General Payments
$1,878.66
74 reported records · 17 companies
Healthcare provider profile · identity verified
Joseph Isaac Chi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1760493464
Verified facts
What the public records show
CMS Open Payments records show Joseph Isaac Chi, MD received $1,878.66 in general payments during 2025 across 74 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Creon, Dovato, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 345 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.87 | 12.0% | 10 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $213.19 | 11.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.83 | 8.4% | 8 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $149.48 | 8.0% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.05 | 7.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $142.47 | 7.6% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $128.37 | 6.8% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $115.34 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.51 | 5.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.27 | 5.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.79 | 4.2% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.28 | 4.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.39 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.50 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.10 | 2.6% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $35.40 | 1.9% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $31.82 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,878.66 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $213.19 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $188.13 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.28 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.05 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $137.96 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $128.37 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $120.96 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $115.34 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $104.37 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $86.21 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $79.79 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $78.28 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.59 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.39 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.61 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.61 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.10 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $35.40 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $31.82 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 345 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 374 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
109 | 43 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
345 | 92 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
374 | 108 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
374 | 108 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 694 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 399 | 113 |
| Jardiance | Empagliflozin | 374 | 108 |
| Nifedipine Er | Nifedipine | 356 | 103 |
| Farxiga | Dapagliflozin Propanediol | 345 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 91 |
| Losartan Potassium | Losartan Potassium | 259 | 76 |
| Meloxicam | Meloxicam | 242 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 81 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 223 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 62 |
| Metformin Hcl | Metformin Hcl | 176 | 64 |
| Alendronate Sodium | Alendronate Sodium | 164 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 53 |
| Gabapentin | Gabapentin | 148 | 58 |
| Simvastatin | Simvastatin | 146 | 42 |
| Eliquis | Apixaban | 145 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 143 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 46 |
| Omeprazole | Omeprazole | 132 | 44 |
| Furosemide | Furosemide | 130 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 34 |
| Azithromycin | Azithromycin | 124 | 104 |
| Glimepiride | Glimepiride | 117 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 35 |
| Linzess | Linaclotide | 109 | 43 |
| Mounjaro | Tirzepatide | 108 | 27 |
| Allopurinol | Allopurinol | 107 | 33 |
| Rybelsus | Semaglutide | 100 | 19 |
| Carvedilol | Carvedilol | 99 | 33 |
| Bumetanide | Bumetanide | 94 | 34 |
| Famotidine | Famotidine | 91 | 33 |
| Xarelto | Rivaroxaban | 91 | 21 |
| Montelukast Sodium | Montelukast Sodium | 89 | 29 |
| Baclofen | Baclofen | 88 | 57 |
| Celecoxib | Celecoxib | 88 | 45 |
| Trazodone Hcl | Trazodone Hcl | 88 | 32 |
| Azelastine Hcl | Azelastine Hcl | 85 | 41 |
| Potassium Chloride | Potassium Chloride | 77 | 32 |
| Ketoconazole | Ketoconazole | 76 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 75 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Lisinopril | Lisinopril | 73 | 17 |
| Ibuprofen | Ibuprofen | 70 | 35 |
| Nabumetone | Nabumetone | 67 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 28 |
| Irbesartan | Irbesartan | 64 | 19 |
| Levofloxacin | Levofloxacin | 64 | 51 |
| Raloxifene Hcl | Raloxifene Hcl | 63 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 16 |
| Entresto | Sacubitril/Valsartan | 52 | 15 |
| Folic Acid | Folic Acid | 52 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 43 |
| Repaglinide | Repaglinide | 49 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 18 |
| Chlorthalidone | Chlorthalidone | 47 | 15 |
| Prednisone | Prednisone | 47 | 30 |
| Promethazine Hcl | Promethazine Hcl | 46 | 35 |
| Sildenafil Citrate | Sildenafil Citrate | 45 | suppressed |
| Vascepa | Icosapent Ethyl | 45 | 16 |
| Lactulose | Lactulose | 44 | 22 |
| Myrbetriq | Mirabegron | 42 | 13 |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Methotrexate | Methotrexate Sodium | 41 | 11 |
| Ozempic | Semaglutide | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 14 |
| Ammonium Lactate | Ammonium Lactate | 35 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 12 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 32 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | 13 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 23 |
| Gemtesa | Vibegron | 28 | suppressed |
| Ofloxacin | Ofloxacin | 28 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 25 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 13 |
| Hydrocortisone | Hydrocortisone | 27 | 13 |
| Temazepam | Temazepam | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 24 | suppressed |
| Naproxen | Naproxen | 24 | 11 |
| Spironolactone | Spironolactone | 24 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | 11 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Lumigan | Bimatoprost | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,878.66 · 74 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Biktarvy, CAPLYTA, CREON, Cologuard Collection Kit, DOVATO, ELIQUIS, EVENITY, Evoke, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PYRUKYND, REPATHA, Rybelsus, VIBERZI, Wegovy, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error